Anakinra - Swedish Orphan Biovitrum

Drug Profile

Anakinra - Swedish Orphan Biovitrum

Alternative Names: Antril; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra

Latest Information Update: 16 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Developer Amgen; Swedish Orphan Biovitrum
  • Class Anti-inflammatories; Recombinant proteins
  • Mechanism of Action Immunomodulators; Interleukin 1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cryopyrin-associated periodic syndromes; Juvenile rheumatoid arthritis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
  • Registered Adult-onset Still's disease; Juvenile rheumatoid arthritis
  • Phase II Gout
  • Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock

Most Recent Events

  • 11 Apr 2018 Registered for Adult-onset Still's disease in Norway, Liechtenstein, Iceland and European Union (SC)
  • 11 Apr 2018 Registered for Juvenile rheumatoid arthritis (In adolescents, In children, In infants) in Norway, Liechtenstein, Iceland and European Union (SC)
  • 23 Feb 2018 Preregistration for Adult-onset Still's disease in European Union (SC) prior to February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top